Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Gets Additional Investment from SEP Capital

NEW YORK (GenomeWeb News) – Med BioGene today said that it has signed an agreement with SEP Capital to sell nearly C$500,000 (US$434,000) in units to the investment firm in a private placement.

The deal comes on the heels of Med BioGene raising C$1.6 million through a private placement last month of 20 million units in two tranches. The Vancouver, BC-based molecular diagnostics firm said that SEP will invest all of its available cash reserves — C$475,979 as of Dec. 31, 2008 — in the placement.

SEP's investment will have the same terms as the private placement completed in June. Each unit is priced at C$.08 and consists of one common share and one-half of one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of C$0.10 for a period of 24 months, subject to the acceleration by MBI of the expiration of the warrants if the closing price of the common shares on the TSX Venture Exchange is greater than C$0.30 for twenty or more consecutive trading days.

Med BioGene said that it will use the proceeds of the private placement for the development and commercialization of its LungExpress Dx and for general corporate purposes. The LungExpress Dx is a gene expression-based test for early-stage, non-small-cell lung cancer that analyzes the molecular profile of a patient's tumor to provide information to assist in tailoring treatment.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.